David Ku, MD
About David Ku, MD
David Ku, M.D. at Jasper Therapeutics
David Ku, M.D. joined Jasper Therapeutics in 2020 and currently holds the title of Vice President, Corporate Development, Portfolio Strategy & Management. In this role, Dr. Ku has spearheaded numerous business development initiatives and financial strategies. His leadership has been pivotal in Jasper’s partnerships with prominent NIH institutes like NHLBI, NIAID, and NCI, as well as with gene therapy partners Graphite Bio and AVROBIO.
David Ku, M.D.'s Role in Raising Capital
David Ku, M.D. has played a crucial role in securing financial resources for Jasper Therapeutics. Under his stewardship, Jasper successfully raised over $100 million in new capital by going public in 2021. His expertise in finance and strategic planning has been instrumental in ensuring the company’s robust financial health.
David Ku, M.D. and Jasper Therapeutics Programs
At Jasper Therapeutics, Dr. David Ku leads the program team for briquilimab (JSP191), focusing on its applications in treating chronic diseases and in stem cell transplants for rare diseases. His oversight ensures that these programs are aligned with the company’s strategic goals and have the necessary resources for development.
David Ku, M.D.'s Professional Background
Before joining Jasper Therapeutics, David Ku, M.D. worked at Gilead in strategic planning where he honed his skills in corporate strategy. Additionally, he has experience as a consultant in the Life Sciences Practice at McKinsey. In this role, he advised biotech and pharma clients on R&D strategy, portfolio management, and asset evaluation.
David Ku, M.D.'s Education
David Ku, M.D. received his M.D. with distinction from the Mount Sinai School of Medicine. He also holds an S.B. in Computer Science from the Massachusetts Institute of Technology (MIT). His educational background provides a solid foundation for his work in the biomedical sector.